Editorial: response to tofacitinib is associated with high rates of long-term treatment persistence

Aliment Pharmacol Ther. 2022 May;55(9):1222-1223. doi: 10.1111/apt.16891.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Piperidines / adverse effects
  • Pyrimidines / adverse effects

Substances

  • tofacitinib
  • Antirheumatic Agents
  • Piperidines
  • Pyrimidines